Abbott Laboratories Stock Buy or Sell? ABT Stocks Forecast

Market Capitalization: 196 439 506 944 $
EBITDA: 7 823 000 064 $
Price to Earnings: 58.6118
Quarterly Earnings Growth YOY: 0.302
Quarterly Revenue Growth YOY: 0.096
Trailing PE: 58.6118
Forward PE: 24.8139
Shares Outstanding: 1772359936

Abbott Laboratories Stock Buy or Sell? ABT Stocks Analytic Forecasts

March 24, 2023 (05:41)

Abbott Laboratories (ABT) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the ABT stock market. Experts share their opinions on what to expect from the Abbott Laboratories stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Abbott Laboratories stocks.

Abbott Laboratories Stock Market Experts’ Analysis and Forecasting – Sell or Buy ABT Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Jonathan Wheeler and is titled

“Abbott Labs: Steadily Getting Back To Normal”

is published on March 20 (2023) and has 4 likes. The review predicts Neutral market trend.

It summarize the following theses:

  • Abbott has had a crazy couple of years, with a formula recall and a COVID testing boom.
  • Through this year, most of that should start to normalize, and the Libre 3 launch and growth in the diabetes market should remain a long-term tailwind for the company.
  • Abbott is a fine hold for dividend safety, but I’d prefer to look elsewhere.

The author starts his analytic review with the following:

Abbott Labs (NYSE:ABT) is in a tough spot to analyze, with a lot of moving parts. The company was at the center of a boom in COVID testing, faced a formula recall at the end of last year, and recently launched its Libre 3 continuous glucose monitor. There’s a ton of give-and-takes in the business, but the company is positioned to continue to reliably grow the dividend, provide returns relatively in-line with the market with smaller drawdowns, and allow investors to sleep well at night.

The opinion of the author can be considered quite authoritative.
The number of 3266 followers confirms this.
Jonathan Wheeler is the contributor of experts community
since 2016 and has 201 works published.

One more noteworthy article is written by Leo Nelissen under the title

“Abbott Laboratories: A Dividend King At A Discount”

on March 20 (2023) and has 12 likes. The expert reflects Bullish trend of the market.

Нis theses make you think about whether to add ABT stocks to your investment portfolio or not, and helps to work out your own Abbott Laboratories stock selling strategies:

  • In this article, we dive into Abbott Laboratories, one of the few dividend kings with a dividend growth track record of at least 50 consecutive annual hikes.
  • The company comes with a decent dividend yield and sustainable dividend growth backed by a wide-moat business model.
  • While fading COVID tailwinds have paused long-term earnings growth, the company benefits from strong secular growth in key areas and an expected total sales rebound in the years ahead.

Leo Nelissen starts analysis with such words:

Introduction In this article, we will do something I should have done a long time ago: discuss Abbott Laboratories (NYSE:ABT), a dividend king in the healthcare sector that finally comes with a terrific valuation.

This author is very popular among the auditory. He has 22223 followers

Leo Nelissen is the contributor of experts community since 2015. Has published at least 1881 articles.

Another analysis presented by Enterprising Investors came out on February 15 (2023). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for ABT stocks. It sounds like

“Abbott Acquires Cardiovascular Systems: Key Takeaways For Investors”

Article has got 1 likes at the moment and forecasting Neutral trend of the market.

Summarizing the information presented in the review concerning the Abbott Laboratories, the expert says the following:

  • Abbott Laboratories expands its cardiovascular pipeline with the relatively small acquisition of Cardiovascular Systems, Inc.
  • Cardiovascular Systems investors get a way out of a cash-burning stock at a decent price. The timing of the deal is opportunistic for Abbott.
  • Abbott offers a strong growth path of 8%+ organic growth over the next couple of years. This acquisition doesn’t change that view immediately.

And here, what comes first:

Abbott Laboratories (NYSE:ABT) is a healthcare growth company with an excellent track record. It showed strong and profitable growth in the past. Cardiovascular Systems, Inc. (NASDAQ:CSII) opens up new growth paths for Abbott.

The opinion of the author can be considered quite authoritative.
The number of 3189 followers confirms this.
Enterprising Investors is the contributor of experts community since 2019. Has already 106 analytic reviews published.

The Share Price of Abbott Laboratories (ABT) for now

What analysts predict: $121.06
52-week high/low: $115.14 / $60.9114

50/200 Day Moving Average: $108.3297 / $104.3559

The average stock price over the previous 50/200 days. For Abbott Laboratories stocks, the 50-day moving average is the resistance level for now. For ABT stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for ABT stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Bright Green Files For U.S. Direct Listing

Buy or Sell BGXX shares? Bright Green Files For U.S. Direct Listing
April 6, 2022
Bright Green Corporation has filed initial information for a direct listing on the Nasdaq Capital Market.

Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock

Buy or Sell LLY shares? Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock
March 23, 2023
84% of shares held by 3370 “institutional” investors, with over 80% of its $315 Billion market capitalization traded in a year.

If You Like Johnson & Johnson, You’ll Love These Higher-Yielding SWANs

Buy or Sell JNJ shares? If You Like Johnson & Johnson, You’ll Love These Higher-Yielding SWANs
March 10, 2023
Recession is coming and with it plenty of scary headlines about crashing stock prices and financial doom.